Gonadotropin-releasing hormone agonist for the preservation of ovarian function in survivors of haematopoietic stem cell transplantation for haematological diseases

Zhenhong Wang1*†, Jian An2† and Chaohua Wang3*

Abstract

Objective: Administration of GnRH agonist (GnRHa) prior to chemotherapy may decreases the risk of gonadal dysfunction in patients with tumors. However, relevant data in haematopoietic stem cell transplantation (HSCT) recipients has not yet been established. Hence, the present study was designed to evaluate the clinical efficacy of GnRHa cotreatment prior to myeloablative regimens on ovarian protection in female survivors of HSCT for haematological diseases.

Patients and methods: Eligible patients were divided into a GnRHa group and a control group. Medical records regarding age at HSCT; diagnosis/indication for HSCT; pre- and posttransplantation serum sex hormone levels; menstruation and perimenopausal symptoms after HSCT were collected and compared. The primary and secondary outcome was the incidence of premature ovarian insufficiency (POI) symptoms associated with hypoestrogenism.

Results: A total of 330 patients were enrolled in the study: 19 patients were lost to follow-up, and clinical information was obtained in 311 patients. There was no significant difference in the primary outcome of follow-up between the two groups (78.50% [84 of 107] for the GnRHa group versus 83.33% [170 of 204] for the control group). The adjusted relative risks (RR) and 95% confidence interval (CI) were 1.19 and 0.73–1.93 (P = 0.487). Among patients who received cotreatment with GnRHa, 62.62% (67 of 107) complained of perimenopausal symptoms, which was significantly lower than the 74.51% (152 of 204) in the control group (adjusted RR: 1.46, 95% CI: 1.04–2.06, P = 0.031).

Conclusion: GnRHa cotreatment may not decrease the POI rate in HSCT survivors. However, it may reduce perimenopausal symptoms in this population, suggesting a potential benefit of GnRHa in clinical practice and warrant further researches.

Keywords: Chemotherapy, Premature ovarian failure, Perimenopausal symptoms, Myeloablative regimen, Leukemia

Introduction

With advances in technology and the increasing numbers of long-term cancer survivors after haematopoietic stem cell transplantation (HSCT), late effects have become the primary concern instead of survival [1–3]. Many haematologic disease survivors of reproductive age face infertility or premature ovarian insufficiency (POI) resulting from exposure to gonadotoxic chemo- and radiotherapy.
prior to HSCT [4, 5]. Thus, more insight has been gained into protection of the ovary to preserve fertility during cancer-related therapy. For female survivors, several options, including embryo cryopreservation, oocyte cryopreservation, ovarian cryopreservation and transposition, and administration of GnRH agonist (GnRHa) have been proposed for preserving fertility [6–8].

Cytotoxic agents cause the apoptosis of follicles, decreasing the levels of estrogens and inhibin and, accordingly, increase the levels of FSH, which stimulates the recruitment of primordial follicles (the so-called “burn-out effect of chemotherapy”) [9]. By binding to GnRH receptors, treatment with GnRHa-a leads to a decrease in the secretion of follicle-stimulating hormone (FSH), and luteinizing hormone (LH), which causes a suppression state that keeps the follicles in a quiescent state, making them less vulnerable to chemo-induced damage [9, 10]. Another potential protective mechanism is the reduction of utero-ovarian perfusion after GnRHa administration, which would also reduce the exposure of follicles to the gonadotoxic effect [11]. Furthermore, GnRHa correlate with the upregulation of the anti-apoptotic molecule sphingosine-1-phosphate (SIP), which inhibits the ceramide pathway involved in chemoinduced apoptosis of the ovarian cells and improves neoangiogenesis in primordial ovarian follicles, resulting in a protective effect in the ovaries [12]. Therefore, according to previous reports, GnRHa cotreatment seems to be an attractive option considering its advantages of safety, noninvasiveness, and feasibility [9, 13].

So far, administration of GnRHa before/during routine chemotherapy may decrease the risk of gonadal dysfunction, and fertility preservation of GnRHa has been investigated in patients with different types of tumors [14–16]. However, the possible utility of this pharmacologic application of preserving ovarian function and fertility in HSCT recipients who have received high chemotherapy dosages in myeloablative regimens and total-body irradiation has not yet been established. Hence, the present study was designed to investigate the benefit of GnRHa on ovarian protection in female survivors of HSCT for haematological diseases and (b) were postmenarchal and aged <40 years old [17]. Patients who were found to have decreased ovarian function before myeloablative chemotherapy were excluded. All patients provided written informed consent prior to participating in the study.

We collected the following data from the medical records of the included patients: age at HSCT; diagnosis/indication for HSCT; total body irradiation (TBI) exposure; alkylator agent exposure; pre- and posttransplantation serum levels of FSH, LH, and estradiol (E2) on days 2–4 of menses; menstruation recovery status and perimenopausal symptoms after HSCT; and duration of outpatient follow-up.

**Treatment**

Every consecutive patient was offered a monthly depot injection of 3.75 mg of GnRHa before HSCT. And patients didn’t receive GnRHa treatment if they rejected, based on voluntariness. The GnRHa administration was timed as early as possible, usually no longer than 7–14 days before starting chemotherapy [18–21]. For patients for whom the haematologists or oncologists recommended the urgent initiation of chemotherapy, the interval was shorter (<7 days). Patients were divided into a GnRHa group and a control group according to whether they received GnRHa cotreatment before the conditioning regimen given prior to HSCT.

**Outcome and evaluation criteria**

The primary outcome was to evaluate the incidence of POI, which was defined as persistent hypergonadotropic amenorrhea (FSH ≥ 25 U/L on at least two occasions) and low E2 levels. We also defined recovery of cyclic ovarian function (COF) as the spontaneous resumption of menses within one year after transplantation. Patients whose FSH levels did not yet meet the diagnostic criteria of POI but who had been given hormone replacement therapy (HRT) were defined as having unknown outcomes.

As secondary objectives, symptoms associated with hypoestrogenism, including hot flashes, mood swings, sleep disturbance, sexual dysfunction, joint/muscle pain, and dysuria/urinary frequency, were recorded once appear and during regular follow-up. And whether the symptoms subsided or not wasn’t recorded. Patients who had suffered from these symptoms before the interview were excluded from analysis.

**Statistical analysis**

Categorical variables are represented by proportions and percentages, and they were compared between groups with the χ² test (Pearson and Fisher’s exact tests). Continuous variables are summed up by their median and interquartile range (IQR), and comparisons...
of two groups were performed using Mann–Whitney U tests. Log-binomial regression models were conducted to estimate the relative risks (RR) for outcomes. \( P < 0.05 \) was considered statistically significant. Statistical analysis was performed using International Business Machines (IBM) Corporation’s Statistical Package for Social Sciences (SPSS) version 24.0 (IBM Corporation, Armonk, New York, USA).

Results
Clinical characteristics of the study population
Between July 2011 and April 2018, 330 eligible patients were enrolled in the study, 19 patients were lost to follow-up, and clinical information could be obtained in 311 patients: 107 in the GnRHa group and 204 in the control group. There were 15 patients in the GnRHa group who required the initiation of myeloablative chemotherapy with a shorter interval. The shortest follow-up was 3 years, and the longest was 5 years. The basal characteristics of the population are described in Table 1. In the GnRHa group, 64.49\% (69 of 107) had standard chemotherapy before the myeloablative regimen, which was significantly lower than the 83.33\% (170 of 204) in the control group \( (P < 0.001) \). There was no significant difference in age, TBI exposure, or pretransplantation serum levels of FSH, LH, and estradiol between the two groups.

Primary objectives: incidence of POI and menses recovery
Overall, 81.67\% (254 of 311) of the patients had POI; 6.11\% (19 of 311) experienced the resumption of menses; and 12.22\% (38 of 311) received HRT but did not have spontaneous resumption of menses and yet met the diagnostic criteria of POI. In the GnRHa group, 78.50\% (84 of 107) had POI versus 83.33\% (170 of 204) in the control group. In contrast, 7.48\% (8 of 107) of patients spontaneously resumed menses in the GnRHa group versus 4.39\% (11 of 204) in the control group. In the GnRHa group, 14.02\% (15 of 107) of patients whose ovarian function was unknown received HRT within one year after HSCT versus 11.27\% (23 of 204) in the control group. There was no significant difference in the primary outcome of follow-up between the two groups \( (P = 0.568) \) (Fig. 1).

Considering that there were fewer patients who had undergone the conventional chemotherapy prior to the myeloablative regimen in the GnRHa group than in the control group, we performed a subgroup analysis to minimize bias. The results showed that 239 patients received chemotherapy prior to the myeloablative regimen for HSCT. In the GnRHa group, 82.61\% (57/69) had POI versus 84.12\% (143/170) in the control group, 2.90\% (2/69) resumed menses versus 2.94\% (5/170) in the control group, and 14.49\% (10/69) had an unknown outcome versus 12.94\% (22/170) in the control group. The difference between the two groups was not statistically significant \( (P = 0.946) \) (see Fig. 2a). Among the 72 patients who did not receive chemotherapy prior to myeloablative

| Table 1 Basal clinical characteristics of the study population |
|---------------------------------------------------------------|
| GnrHa(107) | Control(204) | P     |
|-------------|---------------|-------|
| Age(years)  | 22.86±6.59    | 23.49±6.85 | 0.435 |
| Diagnosis for HSCT |        |       |       |
| Lymphoblastic leukemia | 32(29.91) | 87(42.65) | 0.001 |
| Myeloid leukemia       | 32(29.91) | 77(37.75) |
| Aplastic anemia        | 28(26.17) | 17(8.33)  |
| Myelodysplastic syndrome | 13(12.15) | 19(9.31)  |
| Others                | 2(1.87)   | 4(1.96)   |
| Conventional chemotherapy prior to the myeloablative regimen for HSCT | |
| Yes                    | 69(64.49) | 170(83.33) | <0.001 |
| No                     | 38(35.51) | 34(16.67)  |
| TBI exposure           |           |       |       |
| Yes                    | 2(1.87)   | 8(3.92)   | 0.330 |
| No                     | 105(98.13)| 196(96.08)| /    |
| Alkylator agent exposure |      |       |       |
| Yes                    | 107(100.00)| 204(100.00)| /    |
| No                     |          |         |       |
| Pre-transplantation FSH(mIU/mL) | 8.86±5.27 | 9.31±4.60 | 0.338 |
| Pre-transplantation LH(mIU/mL)  | 8.39±6.13 | 7.45±3.35 | 0.403 |
| Pre-transplantation E2(pg/ml)   | 82.27±60.43| 78.90±37.08| 0.614 |

HCT: Hematopoietic stem cell transplantation, TBI: Total body irradiation, FSH: Follicle-stimulating hormone, LH: Luteinizing hormone, E2: Estradiol

Fig.1 The difference between the GnRHa-treated or untreated patients regarding POI rate in survivors did not reach statistical significance for the study population. POI, premature ovarian insufficiency; COF, cyclic ovarian function
chemotherapy and HSCT, 71.05% (27/38) had POI versus 79.41% (27/34) in the control group, 15.79% (6/38) resumed menses versus 17.65% (6/34) in the control group, and 13.16% (5/38) had an unknown outcome versus 2.94% (1/34) in the control group. The difference between the two groups was not statistically significant (\(P = 0.365\)) (see Fig. 2b).

Log-binomial regression were subsequently applied to determine RR of POI and examine potential influencing factors on POI (Table 2). Compared to women without GnRHa treatment, the unadjusted RR of POI was 1.29 (95% CI: 0.80–2.07, \(P = 0.293\)). There was no statistical significance even after adjusting for factors including conventional chemotherapy prior to the myeloablative regimen for HSCT and TBI exposure. (adjusted RR: 1.19, 95% CI: 0.73–1.93, \(P = 0.487\)).

As expected, the mean FSH and E2 levels were significantly lower in the GnRHa group than in the control group after HSCT, but this difference was no longer observed during the long-term follow-up (Fig. 3).

**Secondary objectives: perimenopausal symptoms**

Perimenopausal symptoms associated with hypoestrogenism were reported in 70.42% (219 of 311) of patients. Among patients who received cotreatment with GnRHa, 62.62% (67 of 107) complained of perimenopausal symptoms, which was significantly lower than the 74.51% (152 of 204) in the control group (RR: 1.47, 95% CI: 1.05–2.06, \(P = 0.027\)). The difference remained statistically significant after adjusting for factors including conventional chemotherapy prior to the myeloablative regimen for HSCT (RR: 1.488, 95% CI: 1.055–2.098, \(P = 0.024\)) and TBI exposure (RR: 1.44, 95% CI: 1.02–2.02, \(P = 0.036\); adjust for two factors simultaneously, RR: 1.46, 95% CI: 1.04–2.06, \(P = 0.031\)).

Of the 6 menopausal symptoms, the order of reported symptoms was mood swings (71.64%, 48 of 67), hot flashes (58.21%, 39 of 67), sleep disturbance (29.85%, 20 of 67), sexual dysfunction (26.87%, 18 of 67), joint/muscle pain (2.99%, 2 of 67), and dysuria/urinary frequency (1.49%, 1 of 67) in the GnRHa group and hot flashes (61.18%, 93 of 152), mood swings (60.53%, 92 of 152), sleep disturbance (39.47%, 60 of 152), sexual dysfunction (35.53%, 54 of 152), joint/muscle pain (12.50%, 19 of 152), and dysuria/urinary frequency (2.63%, 4 of 152) in the control group (Table 3).

**Discussion**

At present, GnRHa treatment is not supported as a proven method for fertility preservation and is considered experimental, with reference to international guidelines [22–24]. Our study did not demonstrate that GnRHa could significantly reduce the incidence of POI in HSCT survivors. To date, only a few studies have addressed the issue of GnRHa efficacy in terms of ovarian protection in HSCT patients to date [25–27]. The results from previous studies have generated a debate concerning the efficacy of GnRHa in fertility preservation after HSCT. Relevant to this highly controversial issue, Blumenfeld
et al [25] compared the incidence of POI after HSCT in young women who received GnRHa cotreatment versus those who did not. The study included 83 patients, and the results showed that the administration of GnRHa increased the rate of cyclic ovarian function in the HSCT survivors from 11 to 38% and decreased the rate of POI from 89 to 62% (P = 0.006). They concluded that GnRHa cotreatment may be beneficial in women undergoing HSCT, especially for lymphoma, providing convincing evidence in support of the efficacy of this preventive strategy. In another prospective study reported by Cheng and coworkers [26], forty four evaluable patients were treated with two doses of 22.5 mg leuprolide before HSCT. After follow-up for a median of 355 days, the researchers found that normal ovarian function was restored in 16% (7/44) of women: 18% (6/33) in the myeloablative group and 9% (1/11) in the nonmyeloablative group (P = 0.66). The authors concluded that GnRHa did not preserve ovarian function in patients who underwent HSCT using either myeloablative or nonmyeloablative regimens. There may be several reasons for the different results generated by the aforementioned similar works.

First, the diagnostic criteria for POI were different in their studies. The study by Blumenfeld et al. defined POI as hypergonadotropin amenorrhea (menopause > 6 months, FSH > 40 U/L), while ovarian failure after transplantation was defined by Cheng and coworkers as the continuation of menstruation cessation for > 3 months in a patient who was premenopausal at the beginning of the study with the following hormonal parameters: (a) serum FSH level > 20 IU/L, (b) serum LH level > 20 IU/L, and (c) serum estradiol level > 30 pmol/L. The diagnostic threshold for FSH is lower and the follow-up time is shorter in Cheng’s research, which indicates insufficient recovery time for ovarian function, leading to a higher incidence of POI. Second, the dosage of GnRHa was different in two studies. Cheng and coworkers administered a higher dose of triptorelin/leuprolide, which led to a 15% (9/59) dropout because of the high rate of intolerable side effects. Third, patients with haematological malignancies in the study by Blumenfeld et al. had started GnRHa cotreatment before first exposure to chemotherapeutic agents. However, GnRH-a was administered before myeloablative chemotherapy preceding HSCT, and almost all

| Table 3 | Number of second perimenopausal symptoms after HSCT and RR at 95% CI (patients with GnRHa treatment or without it) |
|---------|--------------------------------------------------------------------------------------------------------------|
|         | GnRHa(107)                                                                                                     | Control(204)                                                                 | RR(95%CI)a | P     |
| Perimenopausal symptoms |                                                                                                                |                                                                 |             |       |
| Yes     |                                                                                                                |                                                                 |             |       |
| Hot flashes | 67(62.62)                                                                                                       | 152(74.51)                                                                 | 1.47(1.05–2.06) | 0.027 |
| Mood swings | 39                                                                                                               | 93                                                                 |             |       |
| Sleep disturbance | 48                                                                                                               | 92                                                                 |             |       |
| Sexual dysfunction | 20                                                                                                               | 60                                                                 |             |       |
| Joint/muscle pain | 18                                                                                                               | 54                                                                 |             |       |
| Dysuria/urinary frequency | 2                                                                                                               | 19                                                                 |             |       |
| No      |                                                                                                                |                                                                 |             |       |
| Yes     | 40(37.38)                                                                                                       | 52(25.49)                                                                 |             |       |

*a The difference remained statistically significant after adjusting for factors. (RR: 1.488, 95% CI: 1.055–2.098, P = 0.024), adjusted for conventional chemotherapy prior to the myeloablative regimen for HSCT; (RR: 1.44, 95% CI: 1.02–2.02, P = 0.036), adjusted for TBI exposure; (RR: 1.46, 95% CI: 1.04–2.06, P = 0.031), adjust for above two factors simultaneously.
patients received at least one prior chemotherapy regimen. This means that the patients were not protected by GnRHa during chemotherapy prior to the myeloablative regimen and were directly exposed to gonadotoxic chemotherapy drugs, which would have inevitably lead to a higher incidence of POI. Additionally, other studies have discussed the clinical efficacy of GnRHa in survivors of HSCT for haematological diseases [27–29]. Nevertheless, their reference value is limited due to the small objects. Despite the fact that the calculated RR of POI in our study was not statistically significant. The following aspects still deserve to be discussed. The incidence of POI in both the GnRHa group and the control group was lower than the incidence reported in the literature. The main reason is that patients who did not meet the primary end point yet resumed menses after 1 year of follow-up were given HRT therapy thereafter. Therefore, it is impossible to determine whether spontaneous menstruation was restored in patients with unknown outcomes, and some patients whose hormone levels could not meet the diagnostic criteria for POI in our study may have recovered cystic ovarian function. In terms of the timing of GnRHa administration, all patients in this study were given GnRHa before the initiation of myeloablative chemotherapy, and some of the patients in the study population received unprotected gonadal chemotherapy before GnRHa was administered. To eliminate potential bias, we performed a stratified analysis, and the results failed to support the efficacy of GnRHa in HSCT survivors with or without chemotherapy prior to myeloablation. Additionally, it should be noted that hypooestrogenism, caused by POI, is resulting in perimenopausal symptoms, which can have a significant impact on quality of life. Therefore, perimenopausal symptoms and signs of estrogen deficiency are also important reference indicators for evaluating the ovarian protection function of GnRHa. Our study found that GnRHa was able to significantly reduce the incidence of perimenopausal symptoms in HSCT survivors. In addition, although GnRHa does not show the benefits of ovarian protection from the perspective of POI in the present study, we found that FSH levels after HSCT were significantly lower in the GnRHa group than in the control group, indicating a potential effect of ovarian preservation. Thus, GnRHa for the preservation of ovarian function in HSCT survivors is promising and worthy of further investigation.

The main strength of our study is the large-scale population. To the best of our knowledge, this is the largest retrospective study reporting GnRHa cotreatment in HSCT survivors. The main weakness of studies evaluating the role of GnRHa in preserving ovarian function is the retrospective design, with all its inherent risks of bias, which can negatively impact the veracity of the results. The lack of data concerning chemotherapy prior to myeloablative regimens, and uncollected important variables such as BMI, serum AMH level and AFCs, were also both other limitations.

Conclusion
Based on the above, our study did not provide evidence that GnRHa is effective in preventing POI in HSCT survivors. However, it may reduce perimenopausal symptoms in this population, suggesting a potential benefit of GnRHa preservation of ovarian function. We cautiously suggest that GnRHa cotreatment should be considered in clinical practice. These results warrant further examination by researchers with prospective design in the future.

Acknowledgements
Not applicable.

Authors’ contributions
Zhenhong Wang conceptualized the study. Zhenhong Wang and Jian An obtained the data. Jian An analyzed the data. Zhenhong Wang and Jian An wrote the original draft. Chaohua Wang reviewed and edited the manuscript. All authors read and approved the final manuscript.

Funding
Not applicable

Availability of data and materials
The datasets used and/or analysed during the current study available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate
This study was reviewed and approved by the Research Ethics Committee of the Faculty of Medicine of Peking University. All methods were carried out in accordance with relevant guidelines and regulations. This study was performed in compliance with the “Declaration of Helsinki.” The confidentiality and anonymity of the data, and the voluntariness of participation were assured.

Consent for publication
Not applicable

Competing interests
We declare no competing interests regarding the research, authorship, and/or publication of this article.

Author details
1. Department of Gynecology, Fujian Maternity and Child Health Hospital, College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Medical University, Fuzhou, Fujian 350001, PR. China. 2. Department of Gynecology, Women and Children’s Hospital, School of Medicine, Xiamen University, Xiamen 361000, PR. China. 3. Department of Gynecology and Obstetrics, Peking University People’s Hospital, Beijing 100044, PR. China.

Received: 14 August 2022 Accepted: 31 October 2022
Published online: 07 November 2022

References
1. Dvorak CC, Gracia CR, Sanders JE, et al. NHLBI/PBMTC first international conference on late effects after pediatric hematopoietic cell
transplantation: endocrine challenges-thyroid dysfunction, growth impairment, bone health, and reproductive risks. Biol Blood Marrow Transplant. 2011;17(12):1725–38.

2. Letourneau JM, Ebbel EE, Katz PP, et al. Pretreatment fertility counseling and fertility preservation improve quality of life in reproductive-age women with cancer. Cancer. 2012;118(6):1710–7.

3. Joshi S, Savani BN, Chow EJ, et al. Clinical guide to fertility preservation in hematopoietic cell transplant recipients. Bone Marrow Transplant. 2014;49(4):477–84.

4. Guida M, Castaldi MA, Rosamillio R, Gudziev V, Orof O, Sellari C. Reproductive issues in patients undergoing Hematopoietic Stem Cell Transplantation: an update. J Ovarian Res. 2016;9(1):72.

5. Macraan K, Horner E, Panay N. Premature ovarian failure: long-term sequelae. Menopause Int. 2010;16(1):38–41.

6. Georgescu ES, Goldberg JM, du Plessis SS, Agarwal A. Present and future fertility preservation strategies for female cancer patients. Obstet Gynecol Surv. 2008;63(1):725–32.

7. Wallace WH, Anderson RA, Irvine DS. Fertility preservation for young patients with cancer: who is at risk and what can be offered? Lancet Oncol. 2005;6(4):209–18.

8. Lobo RA. Potential options for preservation of fertility in women. N Engl J Med. 2005;353(11):64–73.

9. Blumenfeld Z. How to preserve fertility in young women exposed to chemotherapy? The role of GnRH agonist cotreatment in addition to cryopreservation of embryo, oocytes, or ovaries. Oncologist. 2007;12(9):1044–54.

10. Della Corte L, Barra F, Mercorio, et al. Tolerability considerations for gonadotropin-releasing hormone analogues for endometriosis. Expert Opin Drug Metab Toxicol. 2020;16(9):759–68.

11. Kitajima Y, Endo T, Nagasawa K, et al. Hyperstimulation and a Gonadotropin-releasing Hormone Agonist Modulate Ovarian Vascular Permeability by Altering Expression of the Tight Junction Protein Claudin-5. Endocrinology. 2006;147(2):694–9.

12. Soleiman R, Heytens E, Oktay K. Enhancement of Neangiogenesis and Follicle Survival by Phosphoglycerate-1-Phosphate in Human Ovarian Tissue Xenotransplants. PLoS ONE. 2011;6(4): e19475.

13. Imai A, Sugiyama M, Furui T, Tamaya T, Ohno T. Direct protection by a gonadotropin-releasing hormone analog from doxorubicin-induced granulosa cell damage. Gynecol Obstet Invest. 2007;63(2):102–6.

14. Bedawy MA, Abou-Setta AM, Desai N. Gonadotropin-releasing hormone analog cotreatment for preservation of ovarian function during gonadotoxic chemotherapy: a systematic review and meta-analysis. Fertil Steril. 2011;95(3):906–14.e1–4.

15. Lambertini M, Ceppi M, Poggio F, et al. Ovarian suppression using lutetinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies. Ann Oncol. 2015;26(12):2408–19.

16. Shen YY, Zhang XM, Lv M, et al. Utility of gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage in premenopausal women with breast cancer: a systematic review and meta-analysis. Onco Targets Ther. 2015;8:3349–59.

17. Christin-Maitre S, Givony M, Albare F, et al. Position statement on the diagnosis and management of premature/primary ovarian insufficiency (except Turner Syndrome). Ann Endocrinol (Paris). 2021;82(6):S55–71.

18. Oktay K, Bedoschi G. Appraising the Biological Evidence for and Against the Utility of GnRHa for Preservation of Fertility in Patients With Cancer. J Clin Oncol. 2016;34(22):2563–5.

19. Behringer K, Wildt L, Mueller H, et al. No protection of the ovarian follicle pool with the use of GnRH-analogs or oral contraceptives in young women treated with escalated BEACOPP for advanced-stage Hodgkin lymphoma. Final results of a phase II trial from the German Hodgkin Study Group. Ann Oncol. 2010;21(20):2052–60.

20. Blumenfeld Z, Zur H, Dann Eldad J. Gonadotropin-Releasing Hormone Agonist Cotreatment During Chemotherapy May Increase Pregnancy Rate in Survivors. Oncologist. 2015;20(11):1283–9.

21. Kim SY, Kim SK, Lee JR, Woodruff TK. Toward precision medicine for preserving fertility in cancer patients: existing and emerging fertility preservation options for women. J Gynecol Oncol. 2016;27(2):e22.

22. Oktay K, Harvey BE, Partridge AH, et al. Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol. 2018;36(19):1994–2001.

23. Practice Committee of American Society for Reproductive Medicine. Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion. Fertil Steril. 2019;112(6):1022–33.

24. Peccatori FA, Azim HA Jr, Orecchia R, et al. Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(suppl 6):vi1160–70.

25. Blumenfeld Z, Patel B, Leiba R, Zuckerman T. Gonadotropin-releasing hormone agonist may minimize premature ovarian failure in young women undergoing autologous stem cell transplantation. Fertil Steril. 2012;98(5):1266–70.e1.

26. Cheng YC, Takagi M, Milbourne A, Champlin RE, Ueno NT. Phase II study of gonadotropin-releasing hormone analog for ovarian function preservation in hematopoietic stem cell transplantation patients. Oncologist. 2012;17(2):233–8.

27. Phelan R, Mann E, Napurski C, et al. Ovarian function after hematopoietic cell transplantation: a descriptive study following the use of GnRH agonists for myeloablative conditioning and observation only for reduced-intensity conditioning. Bone Marrow Transplant. 2016;51(10):1369–75.

28. Pup LD, Zanet E, Rupolo M, et al. Which tools may help physicians in female fertility prediction after autologous bone marrow transplantation for lymphoma? A pilot study. J Chemother. 2014;26(5):293–9.

29. Demeestre I, Brice P, Peccatori FA, et al. No Evidence for the Benefit of Gonadotropin-Releaseing Hormone Agonist in Preserving Ovarian Function and Fertility in Lymphoma Survivors Treated With Chemotherapy: Final Long-Term Report of a Prospective Randomized Trial. J Clin Oncol. 2016;34(22):2568–74.